CoChat
Sign Up
Cited by 73

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Ectodomain shedding of the cell adhesion molecule Nectin-4 in ovarian cancer is mediated by ADAM10 and ADAM17

Buchanan, Petra C., Boylan, Kristin L.M., Walcheck, Bruce, Heinze, Rachel, Geller, Melissa A., Argenta, Peter A., Skubitz, Amy P.N.·2017·Journal of Biological Chemistry
DOI 10.1074/jbc.m116.746859
Open this paper in CoChat — free account

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1074/jbc.m116.746859

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Flagged first, then by citations

Research works printed but not linked: 67

  1. Siegel, 2015, Cancer statistics, 2015, CA Cancer J. Clin, 65, 5, 10.3322/caac.21254 · DOI
  2. Perets, 2016, It's totally tubular: riding the new wave of ovarian cancer research, Cancer Res, 76, 10, 10.1158/0008-5472.CAN-15-1382 · DOI
  3. Pradeep, 2014, Hematogenous metastasis of ovarian cancer: rethinking mode of spread, Cancer Cell, 26, 77, 10.1016/j.ccr.2014.05.002 · DOI
  4. Burleson, 2004, Ovarian carcinoma spheroids disaggregate on type I collagen and invade live human mesothelial cell monolayers, Clin. Exp. Metastasis, 21, 685, 10.1007/s10585-004-5768-5 · DOI
  5. Burleson, 2006, Disaggregation and invasion of ovarian carcinoma ascites spheroids, J. Transl. Med, 4, 6, 10.1186/1479-5876-4-6 · DOI
  6. Challita-Eid, 2016, Enfortumab vedotin antibody-drug conjugate targeting Nectin-4 is a highly potent therapeutic agent in multiple preclinical cancer models, Cancer Res, 76, 3003, 10.1158/0008-5472.CAN-15-1313 · DOI
  7. Hibbs, 2004, Differential gene expression in ovarian carcinoma: identification of potential biomarkers, Am. J. Pathol, 165, 397, 10.1016/S0002-9440(10)63306-8 · DOI
  8. Derycke, 2010, Nectin 4 overexpression in ovarian cancer tissues and serum: potential role as a serum biomarker, Am. J. Clin. Pathol, 134, 835, 10.1309/AJCPGXK0FR4MHIHB · DOI
  9. Nabih, 2014, The diagnostic efficacy of nectin 4 expression in ovarian cancer patients, Biomarkers, 19, 498, 10.3109/1354750X.2014.940503 · DOI
  10. Nishiwada, 2015, Nectin-4 expression contributes to tumor proliferation, angiogenesis and patient prognosis in human pancreatic cancer, J. Exp. Clin. Cancer Res, 34, 30, 10.1186/s13046-015-0144-7 · DOI
  11. Lattanzio, 2014, Membranous Nectin-4 expression is a risk factor for distant relapse of T1-T2, N0 luminal-A early breast cancer, Oncogenesis, 3, e118, 10.1038/oncsis.2014.32 · DOI
  12. Takano, 2009, Identification of nectin-4 oncoprotein as a diagnostic and therapeutic target for lung cancer, Cancer Res, 69, 6694, 10.1158/0008-5472.CAN-09-0016 · DOI
  13. Kurita, 2011, Cooperative role of nectin-nectin and nectin-afadin interactions in formation of nectin-based cell-cell adhesion, J. Biol. Chem, 286, 36297, 10.1074/jbc.M111.261768 · DOI
  14. Boylan, 2017, The expression of Nectin-4 on the surface of ovarian cancer cells alters their ability to adhere, migrate, aggregate, and proliferate, Oncotarget, 8, 9717, 10.18632/oncotarget.14206 · DOI
  15. Pavlova, 2013, A role for PVRL4-driven cell-cell interactions in tumorigenesis, Elife, 2, e00358, 10.7554/eLife.00358 · DOI
  16. Ogita, 2008, Cross-talk among integrin, cadherin, and growth factor receptor: roles of nectin and nectin-like molecule, Int. Rev. Cytol, 265, 1, 10.1016/S0074-7696(07)65001-3 · DOI
  17. Fabre-Lafay, 2005, Nectin-4, a new serological breast cancer marker, is a substrate for tumor necrosis factor-α-converting enzyme (TACE)/ADAM-17, J. Biol. Chem, 280, 19543, 10.1074/jbc.M410943200 · DOI
  18. Fabre-Lafay, 2007, Nectin-4 is a new histological and serological tumor associated marker for breast cancer, BMC Cancer, 7, 73, 10.1186/1471-2407-7-73 · DOI
  19. Mullooly, 2016, The ADAMs family of proteases as targets for the treatment of cancer, Cancer Biol. Ther, 17, 870, 10.1080/15384047.2016.1177684 · DOI
  20. Seals, 2003, The ADAMs family of metalloproteases: multidomain proteins with multiple functions, Genes Dev, 17, 7, 10.1101/gad.1039703 · DOI
  21. Horiuchi, 2007, Substrate selectivity of epidermal growth factor-receptor ligand sheddases and their regulation by phorbol esters and calcium influx, Mol. Biol. Cell, 18, 176, 10.1091/mbc.e06-01-0014 · DOI
  22. Nagano, 2004, Cell-matrix interaction via CD44 is independently regulated by different metalloproteinases activated in response to extracellular Ca2+ influx and PKC activation, J. Cell Biol, 165, 893, 10.1083/jcb.200310024 · DOI
  23. Zheng, 2004, Evaluation of the contribution of different ADAMs to tumor necrosis factor α (TNFα) shedding and of the function of the TNFα ectodomain in ensuring selective stimulated shedding by the TNFα convertase (TACE/ADAM17), J. Biol. Chem, 279, 42898, 10.1074/jbc.M403193200 · DOI
  24. Jing, 2015, Identification of an ADAM17 cleavage region in human CD16 (FcγRIII) and the engineering of a non-cleavable version of the receptor in NK cells, PLoS One, 10, e0121788, 10.1371/journal.pone.0121788 · DOI
  25. Mullooly, 2015, ADAM10: a new player in breast cancer progression?, Br. J. Cancer, 113, 945, 10.1038/bjc.2015.288 · DOI
  26. Yuan, 2013, ADAM10 is overexpressed in human hepatocellular carcinoma and contributes to the proliferation, invasion and migration of HepG2 cells, Oncol. Rep, 30, 1715, 10.3892/or.2013.2650 · DOI
  27. McGowan, 2008, ADAM-17 predicts adverse outcome in patients with breast cancer, Ann. Oncol, 19, 1075, 10.1093/annonc/mdm609 · DOI
  28. Gyorffy, 2012, Implementing an online tool for genome-wide validation of survival-associated biomarkers in ovarian-cancer using microarray data from 1287 patients, Endocr. Relat. Cancer, 19, 197, 10.1530/ERC-11-0329 · DOI
  29. Le Gall, 2009, ADAMs 10 and 17 represent differentially regulated components of a general shedding machinery for membrane proteins such as transforming growth factor α, l-selectin, and tumor necrosis factor α, Mol. Biol. Cell, 20, 1785, 10.1091/mbc.e08-11-1135 · DOI
  30. Sheppard, 1998, Aryl ketones as novel replacements for the C-terminal amide bond of succinyl hydroxamate MMP inhibitors, Bioorg. Med. Chem. Lett, 8, 3251, 10.1016/S0960-894X(98)00597-6 · DOI
  31. Georgiadis, 2008, Specific targeting of metzincin family members with small-molecule inhibitors: progress toward a multifarious challenge, Bioorg. Med. Chem, 16, 8781, 10.1016/j.bmc.2008.08.058 · DOI
  32. Ott, 2008, Potent, exceptionally selective, orally bioavailable inhibitors of TNF-α converting enzyme (TACE): novel 2-substituted-1H-benzo[d]imidazol-1-yl)methyl)benzamide P1′ substituents, Bioorg. Med. Chem. Lett, 18, 1577, 10.1016/j.bmcl.2008.01.075 · DOI
  33. Wang, 2013, ADAM17 cleaves CD16b (FcγRIIIb) in human neutrophils, Biochim. Biophys. Acta, 1833, 680, 10.1016/j.bbamcr.2012.11.027 · DOI
  34. Tape, 2011, Cross-domain inhibition of TACE ectodomain, Proc. Natl. Acad. Sci. U.S.A, 108, 5578, 10.1073/pnas.1017067108 · DOI
  35. Hundhausen, 2003, The disintegrin-like metalloproteinase ADAM10 is involved in constitutive cleavage of CX3CL1 (fractalkine) and regulates CX3CL1-mediated cell-cell adhesion, Blood, 102, 1186, 10.1182/blood-2002-12-3775 · DOI
  36. Cerami, 2012, The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data, Cancer Discov, 2, 401, 10.1158/2159-8290.CD-12-0095 · DOI · Paper page
  37. Gao, 2013, Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal, Sci. Signal, 6, pl1, 10.1126/scisignal.2004088 · DOI · Paper page
  38. 2011, Integrated genomic analyses of ovarian carcinoma, Nature, 474, 609, 10.1038/nature10166 · DOI · Paper page
  39. Wang, 2009, Regulation of mature ADAM17 by redox agents for l-selectin shedding, J. Immunol, 182, 2449, 10.4049/jimmunol.0802770 · DOI
  40. Wang, 2011, Different signaling pathways stimulate a disintegrin and metalloprotease-17 (ADAM17) in neutrophils during apoptosis and activation, J. Biol. Chem, 286, 38980, 10.1074/jbc.M111.277087 · DOI
  41. Lemjabbar-Alaoui, 2011, TACE/ADAM-17 phosphorylation by PKC-epsilon mediates premalignant changes in tobacco smoke-exposed lung cells, PLoS One, 6, e17489, 10.1371/journal.pone.0017489 · DOI
  42. Yin, 2009, ERK1/2 mediate wounding- and G-protein-coupled receptor ligands-induced EGFR activation via regulating ADAM17 and HB-EGF shedding, Invest. Ophthalmol. Vis. Sci, 50, 132, 10.1167/iovs.08-2246 · DOI
  43. Hurst, 2012, siRNA knockdown of ADAM-10, but not ADAM-17, significantly reduces fractalkine shedding following pro-inflammatory cytokine treatment in a human adult brain endothelial cell line, Neurosci. Lett, 521, 52, 10.1016/j.neulet.2012.05.057 · DOI
  44. Ren, 2006, Lysophosphatidic acid is constitutively produced by human peritoneal mesothelial cells and enhances adhesion, migration, and invasion of ovarian cancer cells, Cancer Res, 66, 3006, 10.1158/0008-5472.CAN-05-1292 · DOI
  45. Cao, 2015, Diagnostic value of plasma lysophosphatidic acid levels in ovarian cancer patients: A case-control study and updated meta-analysis, J. Obstet. Gynaecol. Res, 41, 1951, 10.1111/jog.12806 · DOI
  46. Rosendahl, 1997, Identification and characterization of a pro-tumor necrosis factor-α-processing enzyme from the ADAM family of zinc metalloproteases, J. Biol. Chem, 272, 24588, 10.1074/jbc.272.39.24588 · DOI
  47. Maskos, 1998, Crystal structure of the catalytic domain of human tumor necrosis factor-α-converting enzyme, Proc. Natl. Acad. Sci. U.S.A, 95, 3408, 10.1073/pnas.95.7.3408 · DOI
  48. Le Gall, 2010, ADAM17 is regulated by a rapid and reversible mechanism that controls access to its catalytic site, J. Cell Sci, 123, 3913, 10.1242/jcs.069997 · DOI
  49. Blobel, 1997, Metalloprotease-disintegrins: links to cell adhesion and cleavage of TNF α and Notch, Cell, 90, 589, 10.1016/S0092-8674(00)80519-X · DOI
  50. Janes, 2005, Adam meets Eph: an ADAM substrate recognition module acts as a molecular switch for ephrin cleavage in trans, Cell, 123, 291, 10.1016/j.cell.2005.08.014 · DOI
  51. Blobel, 2000, Remarkable roles of proteolysis on and beyond the cell surface, Curr. Opin. Cell Biol, 12, 606, 10.1016/S0955-0674(00)00139-3 · DOI
  52. Blobel, 2005, ADAMs: key components in EGFR signalling and development, Nat. Rev. Mol. Cell Biol, 6, 32, 10.1038/nrm1548 · DOI
  53. Lorenzen, 2016, Control of ADAM17 activity by regulation of its cellular localisation, Sci. Rep, 6, 35067, 10.1038/srep35067 · DOI
  54. Poersch, 2016, A proteomic signature of ovarian cancer tumor fluid identified by high-throughput and verified by targeted proteomics, J. Proteomics, 145, 226, 10.1016/j.jprot.2016.05.005 · DOI
  55. Ohta, 2003, Ki16425, a subtype-selective antagonist for EDG-family lysophosphatidic acid receptors, Mol. Pharmacol, 64, 994, 10.1124/mol.64.4.994 · DOI
  56. McPherson, 2016, Divergent modes of clonal spread and intraperitoneal mixing in high-grade serous ovarian cancer, Nat. Genet, 48, 758, 10.1038/ng.3573 · DOI
  57. Baudhuin, 2002, Akt activation induced by lysophosphatidic acid and sphingosine-1-phosphate requires both mitogen-activated protein kinase kinase and p38 mitogen-activated protein kinase and is cell-line specific, Mol. Pharmacol, 62, 660, 10.1124/mol.62.3.660 · DOI
  58. Matte, 2015, Ovarian cancer ascites enhance the migration of patient-derived peritoneal mesothelial cells via cMet pathway through HGF-dependent and -independent mechanisms, Int. J. Cancer, 137, 289, 10.1002/ijc.29385 · DOI
  59. Bellacosa, 1995, Molecular alterations of the AKT2 oncogene in ovarian and breast carcinomas, Int. J. Cancer, 64, 280, 10.1002/ijc.2910640412 · DOI
  60. Larue, 2005, Epithelial-mesenchymal transition in development and cancer: role of phosphatidylinositol 3′ kinase/AKT pathways, Oncogene, 24, 7443, 10.1038/sj.onc.1209091 · DOI
  61. Duffy, 2011, The ADAMs family of proteases: new biomarkers and therapeutic targets for cancer?, Clin. Proteomics, 8, 9, 10.1186/1559-0275-8-9 · DOI
  62. Dinh, 2008, New therapies for ovarian cancer: cytotoxics and molecularly targeted agents, Crit. Rev. Oncol. Hematol, 67, 103, 10.1016/j.critrevonc.2008.01.012 · DOI
  63. Glaysher, 2013, Targeting EGFR and PI3K pathways in ovarian cancer, Br. J. Cancer, 109, 1786, 10.1038/bjc.2013.529 · DOI
  64. Pruessmeyer, 2014, Leukocytes require ADAM10 but not ADAM17 for their migration and inflammatory recruitment into the alveolar space, Blood, 123, 4077, 10.1182/blood-2013-09-511543 · DOI
  65. Haley, 2016, Functional characterization of a panel of high-grade serous ovarian cancer cell lines as representative experimental models of the disease, Oncotarget, 7, 32810, 10.18632/oncotarget.9053 · DOI
  66. Mishra, 2015, Regulation of CXCR2 expression and function by a disintegrin and metalloprotease-17 (ADAM17), J. Leukoc. Biol, 97, 447, 10.1189/jlb.3HI0714-340R · DOI
  67. Schneider, 2012, NIH Image to ImageJ: 25 years of image analysis, Nat. Methods, 9, 671, 10.1038/nmeth.2089 · DOI · Paper page

Cited by

Sorted by citations

Metadata

Authors
Buchanan, P. C., Boylan, K. L. M., Walcheck, B., Heinze, R., Geller, M. A., Argenta, P. A., & Skubitz, A. P. N.
Venue
Journal of Biological Chemistry
Publisher
Elsevier BV
Published
2017-04
Volume
292
Issue
15
Pages
6339-6351
ISSN
0021-9258
DOI
10.1074/jbc.m116.746859
Cited by
73
References
1
Language
en
Licence
Funders
National Institutes of Health (R01 CA203348, P30 CA77598)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review